Arbutus Biopharma
ABUS
ABUS
153 hedge funds and large institutions have $340M invested in Arbutus Biopharma in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 41 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
153
Holders Change
+9
Holders Change %
+6.25%
% of All Funds
2.04%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
22
Increased
55
Reduced
41
Closed
13
Calls
$2.41M
Puts
$2.35M
Net Calls
+$57K
Net Calls Change
-$7.07M
Top Buyers
| 1 |
1
Morgan Stanley
New York
|
$73.9M |
| 2 |
2
JPMorgan Chase & Co
New York
|
$2.93M |
| 3 |
3
BlackRock
New York
|
$42.3M |
| 4 |
4
State Street
Boston,
Massachusetts
|
$16.4M |
| 5 |
WCM
5
Whitefort Capital Management
New York
|
$43.3M |
